NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the NeoGenomics second quarter 2026 financial results call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. I will now turn the call over to Abhishek Jain, Chief Financial Officer. Before we begin, I would like to introduce Andrew Brackman, who recently joined NeoGenomics as our new Vice President of Investor Relations. Andrew spent nearly a decade in sell-side equity research covering the diagnostic sector. He also covered neogenomics directly, giving him a deep understanding of both the company and its competitive landscape. Beyond his analytical depth, Andrew is known for building genuine, long-term relationships with the people he works with. We're excited to have Andrew on board to lead and shape our investor relations strategy and deepen our relationships across the investor and analyst community. Now let me turn the call over to Andrew to get us started. Andrew? Thank you, Abhishek, and good afternoon, everyone. I am excited to be joining Neogenomics in this role. Having covered the stock for the last eight years during my time at William Blair, I have been inspired by the team's ability to leverage its well-earned channel strength to provide new and holistic testing solutions for patients. I see this strategy as driving durable, profitable growth that betters Neo over the long term for all stakeholders. Recent new product launches further expanding growth opportunities across large end markets. Now is a great time to join the company. In this role, it is my goal to partner with the investment community in an ongoing effort to better articulate and communicate our strategy and differentiation. This is something I believe to be a real opportunity to improve upon...